Peptic Ulcer Disease and NSAID-Associated Ulcers: Pharmacotherapy

Distinguish the Underlying Ulcer Mechanism

Peptic ulcers disrupt the gastric or duodenal mucosa. H. pylori infection and exposure to nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, are major causes. NSAIDs reduce protective prostaglandin synthesis through cyclooxygenase inhibition, impairing bicarbonate and mucus secretion, mucosal perfusion, and repair. In contrast, H. pylori requires eradication; prolonged acid suppression without antimicrobial treatment does not eliminate the organism (Chaudhry & Corder, 2026).

Symptoms are not diagnostic: epigastric discomfort may represent dyspepsia, GERD, functional disease, malignancy, or cardiac pathology. Hematemesis, melena, syncope, hemodynamic compromise, rigid abdomen, severe sudden abdominal pain, and obstructive symptoms require urgent evaluation. Upper endoscopy establishes ulcer diagnosis and evaluates selected complications (Chaudhry & Corder, 2026; Laine et al., 2021).

Initial Decision Pathway

Presentation	Clinical decision	What changes management
New uninvestigated dyspepsia	In adults 60 years or older, upper endoscopy is generally suggested; in younger patients, consider noninvasive H. pylori test-and-treat before empiric PPI if positive.	Modify for malignancy risk, alarm findings, previous ulcer, and the clinical picture. This is a dyspepsia framework, not a substitute for acute-bleeding triage.
Confirmed H. pylori-positive ulcer	Initiate guideline-concordant eradication therapy and plan objective test of cure.	Use the dedicated H. pylori page for 2024 ACG regimens; avoid empiric clarithromycin triple therapy without confirmed susceptibility (Chey et al., 2024).
NSAID-associated ulcer, stable	Stop the causative NSAID when feasible; prescribe a therapeutic PPI course and evaluate H. pylori.	An 8-week full-dose PPI pathway is supported for NSAID-associated ulcers in NICE guidance. Evaluate need for ongoing NSAID and protective therapy.
Ulcer bleeding or perforation concern	Emergency stabilization and endoscopic/surgical evaluation, as indicated; oral PPI monotherapy is insufficient.	After successful endoscopic hemostasis of a high-risk bleeding ulcer, follow the guideline-directed high-dose PPI sequence.

For dyspepsia, an endoscopy threshold at age 60 does not override individualized urgent assessment in younger patients with dangerous findings. A negative or treated H. pylori test should not stop investigation when symptoms persist or red flags arise (Moayyedi et al., 2017).

Therapeutic Classes: Match Mechanism to Indication

Medication strategy	Best-supported role	Safety or selection issue
Proton pump inhibitors (PPIs)	Most effective routine acid suppression for healing NSAID-related ulcers; preferred gastroprotection when a high-risk patient must continue an NSAID.	Review adherence, dosing before meals for most formulations, chronic indication, and interactions. Duration depends on ulcer type and complication.
H2-receptor antagonists (H2RAs)	Can heal selected uncomplicated ulcers; less potent for gastric ulcer prevention during continued NSAID exposure.	Renal dose adjustment may be required. Do not equate standard-dose H2RA with PPI protection for high-risk NSAID use.
Misoprostol	Prostaglandin E1 analog approved to reduce NSAID-induced gastric ulcer risk in high-risk patients.	Diarrhea/cramping limit adherence; boxed pregnancy risk and contraindication to ulcer prophylaxis in pregnancy. Not a substitute for H. pylori eradication.
Sucralfate	Topical mucosal protection for selected ulcers when the offending NSAID has been stopped.	Multiple daily doses; binds other oral drugs; constipation and aluminum accumulation concerns in renal disease.
H. pylori antimicrobial regimens	Definitive infection eradication alongside potent acid suppression.	Regimen choice reflects allergy, resistance, previous macrolide/quinolone exposure, adherence, and test-of-cure planning.

NSAID Risk Stratification and Gastroprotection

Prior complicated ulcer or bleeding, older age, high NSAID dosage, concomitant anticoagulants or antiplatelets, and concurrent corticosteroids raise concern for gastrointestinal complications. Risk reduction starts with stopping an unnecessary NSAID, selecting the lowest effective dose for the shortest feasible duration, and considering a non-NSAID analgesic. When an NSAID is unavoidable in a patient with prior ulceration, a PPI accompanies an appropriately selected regimen; COX-2 selectivity does not eliminate bleeding or cardiovascular risk (Chaudhry & Corder, 2026; National Institute for Health and Care Excellence, 2014).

Low-dose aspirin for secondary cardiovascular prevention creates a different risk-benefit decision from elective NSAID analgesia. For aspirin used for secondary cardiovascular prevention, ACG–CAG guidance suggests against routine interruption during GI bleeding; if withheld, resume on the day endoscopic hemostasis is confirmed. Management of P2Y12 inhibitors and dual-antiplatelet regimens requires individualized GI/cardiology coordination rather than extrapolation of the aspirin recommendation (Abraham et al., 2022). This issue merits an individualized plan rather than a blanket deprescribing rule (Laine et al., 2021).

Representative Adult Pharmacotherapy

Medication	Example adult approach	Clinical qualification
Omeprazole	Adult active duodenal ulcer: 20 mg orally once daily for 4 weeks (some patients require 4 additional weeks); active benign gastric ulcer: 40 mg once daily for 4–8 weeks.	These are indication-specific delayed-release capsule label doses, not interchangeable regimens for every ulcer etiology. For NSAID-associated ulcers, separately evaluate the need for the NSAID, gastroprotection, and healing follow-up. (Redpharm Drug, 2025).
Pantoprazole	40 mg orally daily in common clinician-directed therapeutic acid-suppression regimens.	Dose and duration may be off-label depending on the precise ulcer indication. Confirm the selected product label.
Misoprostol	200 mcg orally four times daily with meals and at bedtime throughout NSAID exposure; 100 mcg may be used if 200 mcg is not tolerated.	FDA-labeled NSAID-induced gastric ulcer risk reduction; do not use for that indication during pregnancy. Verify contraception, pregnancy-related warnings, and tolerability.
Sucralfate	1 g orally four times daily in selected ulcer-healing regimens.	Separate from interacting oral agents; review renal impairment and dosing burden.

These are adult educational examples, not comprehensive prescriptions. Compare the contemplated indication with product labeling and comorbidities before use; bleeding ulcers follow a separate inpatient pathway (Chaudhry & Corder, 2026; Pfizer Laboratories, 2026; Laine et al., 2021).

Gastroprotection Is Not the Same as a PPI for All NSAID Users

For patients requiring NSAIDs, distinguish baseline GI risk, cardiovascular risk, and bleeding-risk medications before selecting NSAID/COX-2 strategy plus PPI. In a patient receiving clopidogrel, avoid omeprazole or esomeprazole per Plavix labeling; pantoprazole has less effect on clopidogrel platelet inhibition. Do not stop indicated clopidogrel or withhold necessary GI protection without coordinating the competing thrombotic and hemorrhagic risks (Sanofi-Aventis U.S. LLC, 2025; Laine et al., 2021).

Misoprostol is an alternative for reducing NSAID-induced gastric-ulcer risk in appropriately selected nonpregnant patients, not for H. pylori eradication or rescue of active GI hemorrhage. Cytotec labeling specifies 200 micrograms orally four times daily with food and at bedtime (100 micrograms if 200 micrograms is not tolerated) during NSAID exposure; significant diarrhea and uterotonic pregnancy hazards sharply restrict its suitability (Pfizer Laboratories, 2026).

High-Risk Upper-GI Bleeding: Separate Inpatient Pathway

For hospitalized patients with upper-GI bleeding, the ACG suggests upper endoscopy within 24 hours after presentation, following appropriate resuscitation. Ulcers with active hemorrhage or a nonbleeding visible vessel warrant endoscopic therapy. After successful hemostasis, high-dose PPI therapy is recommended continuously or intermittently for 72 hours, followed by twice-daily oral PPI through the first 2 weeks after endoscopy in high-risk cases. Rebleeding prompts repeat endoscopy; failed endoscopic hemostasis may lead to transcatheter embolization (Laine et al., 2021).

A patient with melena, hypotension, and NSAID exposure is not an appropriate candidate for routine outpatient dyspepsia management, even if epigastric pain improves after an antacid. Address stabilization, blood loss, and definitive control of hemorrhage first (Laine et al., 2021).

Monitoring, Follow-Up, and Treatment Failure

• Document ulcer etiology, previous ulcer or bleed, NSAID/aspirin exposure, concurrent antithrombotics, H. pylori result and eradication plan, pain pattern, and baseline anemia/renal status where relevant.
• Assess adherence, correct PPI administration, symptom trajectory, ongoing NSAID exposure, adverse effects, and evidence of continued bleeding at follow-up.
• For treated H. pylori, test eradication at least 4 weeks after antibiotics/bismuth, with PPIs or potassium-competitive acid blockers withheld for 2 weeks before testing; do not use symptom relief or serology as proof of cure (Chey et al., 2024).
• Gastric ulcers may require repeat endoscopy to verify healing and exclude malignancy. Unhealed ulceration requires evaluation for continued NSAIDs, adherence, missed/persistent H. pylori, malignancy, and rare hypersecretory disease.
• Review whether post-healing maintenance acid suppression is justified by an ongoing risk such as continued NSAID therapy or previous complicated ulcer rather than extending it automatically.

Ulcer Healing Is Not the Same as Symptom Resolution

For an uncomplicated duodenal ulcer, an appropriate acid-suppression course and eradication of H. pylori when present are usually sufficient to support healing. Gastric ulcers warrant a lower threshold for endoscopic biopsy and confirmation of healing when malignancy is a concern, ulcer features are suspicious, or symptoms fail to resolve; surveillance practices depend on endoscopic findings and local specialty guidance. Persistent symptoms should prompt assessment of continued NSAID/aspirin use, adherence, H. pylori eradication, alternative diagnoses and an unrecognized complication rather than automatic indefinite escalation of PPI dose (Chaudhry & Corder, 2026).

H. pylori test of cure is required after eradication therapy regardless of dyspepsia relief; a prolonged PPI course must not obscure the washout needed before testing. Healing outcomes and eradication outcomes are separate documentation fields (Chey et al., 2024).

NSAIDs, Antiplatelets and Cardiovascular Indication Must Be Reconciled Together

First determine whether the NSAID can be stopped or replaced by an appropriate non-NSAID pain strategy. In a patient who truly requires an NSAID and has substantial ulcer risk, the least effective NSAID exposure, a selective COX-2 approach when cardiovascular profile permits, and PPI gastroprotection may be considered. A COX-2 inhibitor does not eliminate ulcer risk; it may be unsuitable with high cardiovascular risk. Misoprostol can prevent NSAID-associated gastric ulcers but tolerability and pregnancy contraindications limit its role (Chaudhry & Corder, 2026).

Aspirin for primary prevention and aspirin for secondary prevention are not equivalent decisions. In a patient with a coronary stent, ischemic stroke or established coronary disease, prolonged interruption of needed antiplatelet therapy can create major cardiovascular harm. Coordinate decisions on resumption with gastroenterology and the responsible cardiovascular team after hemostasis, and use indicated PPI protection. Do not advise stopping all aspirin indefinitely because an ulcer was found. Also reconcile PPI selection when clopidogrel is prescribed (Laine et al., 2021).

After Bleeding or Rebleeding: Define the Inpatient and Outpatient Endpoints

Hematemesis, melena with hemodynamic symptoms, orthostasis, syncope or falling hemoglobin requires emergency evaluation, resuscitation and risk-directed endoscopy. Following endoscopic control of a high-risk bleeding lesion, high-dose PPI treatment and appropriate timing of resumption of antithrombotic therapy are specialized decisions. Before discharge, document ulcer etiology, H. pylori status, avoidance of unnecessary NSAIDs, indicated gastroprotection, treatment adherence and follow-up evaluation. Recurrence despite management warrants endoscopic and medication review (Laine et al., 2021).

Decision pathway: Ulcer setting

Ulcer setting	Treatment and follow-up target	Key competing risk
H. pylori-related duodenal ulcer	Eradication plus adequate acid suppression; confirm active-infection cure.	False-negative cure testing due to early test or acid suppression.
Gastric ulcer / suspicious lesion	Acid suppression, biopsy or endoscopic assessment and healing follow-up when indicated.	Missed malignancy despite symptom resolution.
NSAID-dependent patient with high GI risk	Reconsider analgesic; use protective strategy if NSAID necessary.	COX-2 cardiovascular risk and incomplete GI protection.
Bleeding ulcer + secondary-prevention aspirin	Hemostasis, PPI treatment, multidisciplinary antiplatelet plan.	Preventable thrombosis from extended aspirin withdrawal; rebleeding if protection omitted.

Applied Clinical Case and Prescribing Rationale

Scenario: A 70-year-old with coronary disease after PCI, CKD and prior upper-GI bleed uses ibuprofen daily for osteoarthritis and takes aspirin plus clopidogrel. A new gastric ulcer is found without active bleeding. What decisions cannot be made in isolation?

Reasoned response: NSAID substitution, PPI gastroprotection, ulcer biopsy/healing plan, H. pylori testing and antiplatelet reconciliation are interdependent. Avoid casually stopping secondary-prevention antiplatelets. Omeprazole/esomeprazole interactions with clopidogrel should inform PPI selection. CKD increases harm from routine NSAIDs. The end point includes documented healing assessment as indicated and eradication confirmation if H. pylori is present (Laine et al., 2021; Chey et al., 2024).

High-Yield Distinctions

Related YourDNP Resources

Pharmacology learning hub | H. pylori Eradication | GERD Pharmacotherapy

---

---

References

Abraham, N. S., Barkun, A. N., Sauer, B. G., Douketis, J., Laine, L., Noseworthy, P. A., Telford, J. J., & Leontiadis, G. I. (2022). American College of Gastroenterology–Canadian Association of Gastroenterology clinical practice guideline: Management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period. American Journal of Gastroenterology, 117(4), 542–558. https://doi.org/10.14309/ajg.0000000000001627

Chaudhry, F., & Corder, M. M. (2026). Peptic ulcer disease. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 19). McGraw Hill.

Chey, W. D., Howden, C. W., Moss, S. F., Morgan, D. R., Greer, K. B., Grover, S., & Shah, S. C. (2024). ACG clinical guideline: Treatment of Helicobacter pylori infection. American Journal of Gastroenterology, 119(9), 1730–1753. https://doi.org/10.14309/ajg.0000000000002968

Laine, L., Barkun, A. N., Saltzman, J. R., Martel, M., & Leontiadis, G. I. (2021). ACG clinical guideline: Upper gastrointestinal and ulcer bleeding. American Journal of Gastroenterology, 116(5), 899–917. https://doi.org/10.14309/ajg.0000000000001245

Moayyedi, P. M., Lacy, B. E., Andrews, C. N., Enns, R. A., Howden, C. W., & Vakil, N. (2017). ACG and CAG clinical guideline: Management of dyspepsia. American Journal of Gastroenterology, 112(7), 988–1013. https://doi.org/10.1038/ajg.2017.154

National Institute for Health and Care Excellence. (2014). Gastro-oesophageal reflux disease and dyspepsia in adults: Investigation and management (CG184). https://www.nice.org.uk/guidance/cg184/chapter/Recommendations

Pfizer Laboratories. (2026, June 4). Cytotec (misoprostol) tablets [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ab12da7-5731-4e06-bf1c-bc3f2e711f12

Redpharm Drug. (2025, December 25). Omeprazole delayed-release capsules [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fd1acb8-12dc-70b7-e063-6394a90a0399

Sanofi-Aventis U.S. LLC. (2025, May 30). Plavix (clopidogrel bisulfate) tablets [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de8b0b67-eb25-4684-83b5-7ad785314227